natgillin/translations-raw huggingface dataset:
The compound according to any one of claims 1 to 4 or a pharmacologically acceptable salt thereof, wherein V represents a single bond or a methylene group, R2 represents a methyl group, a cyclohexyl group, a tetrahydropyranyl group, or a piperidyl group, and R3 represents a methyl group, wherein the cyclohexyl group, the tetrahydropyranyl group, and the piperidyl group each have one substituent independently selected from the group consisting of a methyl group, an ethyl group, an ethylsulfonyl group, a methylamino group, a dimethylamino group, and an ethylmethylamino group. 
Spoj u skladu sa bilo kojim od patentnih zahtjeva 1 do 4 ili farmakološki prihvatljiva sol istog, gdje V predstavlja jednostruku vezu ili metilen grupu, predstavlja metil grupu, cikloheksil grupu, tetrahidropiranil grupu, ili piperidil grupu, i predstavlja metil grupu, gdje cikloheksil grupa, tetrahidropiranil grupa, i piperidil grupa svaka ima jedan supstituent nezavisno odabran iz grupe koja se sastoji od metil grupe, etil grupe, etilsulfonil grupe, metilamino grupe, dimetilamino grupe, i etilmetilamino grupe.
8.1, 15.8 and 16.5 degrees 2theta±0.2 degrees 2theta. The polymorph of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride as claimed in claim 2, which is polymorph 2 and has at least reflection in an X-ray powder diffractogram using CuKa1 radiation at 
Polimorf 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida prema zahtjevu 2, naznačen time da je polimorf 2 i ima refleksiju u difraktogramu X-zraka na prahu korištenjem CuKa; zračenja barem kod 8.1, 15.8, 16.5, 22.2, 25,01 26.6 stupnjeva 2theta + 0.2 stupnjeva 2theta.
Pull-out mechanism according to claim 3 characterised in that at least one auxiliary wheel (24a", 24b"), which is placed between the elevated auxiliary rail (7") and the upper rail (6"), is mounted to the upper rail (6"). 
Mehanizam za izvlačenje ladice u skladu s patentnim zahtjevom 3, naznačen time što je najmanje jedan pomoćni kotač (24a ̋, 24b ̋), koji je smješten između pomoćne tračnice (7 ̋) koja je podignuta i gornje tračnice (6 ̋), postavljen na gornju tračnicu (6 ̋).
is selected from t-butyl, methyl, isopropyl and phenyl. 
R4 je odabrano od t-butila, metila, izopropila i fenila.
A process as in Claim 1 or Claim 2, wherein the first ether solvent is present in an amount in the range of about 7% to about 10% by volume. 
Proces prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time da je prvo etersko otapalo prisutno u količini u rasponu od oko 7% do oko 10% po volumenu.
A blended wax according to claim 4 wherein the one or more organic resins comprise one or more selected from the group comprising: Rosin, Rosin derivatives, Rosin esters. 
Miješani vosak u skladu s patentnim zahtjevom 4, naznačen time što je jedna ili više organskih smola jedna ili više tvari koje se bira iz skupine koju čine: kolofonij, derivati kolofonija, esteri kolofonija.
The pharmaceutical composition according to claim 1, wherein Form I is characterized as a crystal form having a monoclinic crystal system, a P21/n space group, and the following unit cell dimensions: 
dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2il)benzoeve kiseline prema zahtjevu 1 koji ima monoklinski kristalni sustav, P2,/n prostornu grupu, i sljedeće dimenzije elementarnih stanica:
The IL-18BP preparation obtained from the purification process of the invention may contain less than 20 % of impurities, preferably less than 10%, 5%, 3%, 2% or 1% of impurities, or it may be purified to homogeneity, i.e. being free from any proteinaceous contaminants. 
Preparirani IL-18BP koji je dobiven s pomoću procesa pročišćavanja iz ovoga izuma može sadržavati manje od 20% nečistoća, poželjno manje od 10%, 5%, 3%, 2% ili 1% ili može biti potpuno homogen primjerice takav da ne sadrži bilo kakve proteinske nečistoće.
The formulations can be provided in single or multi-dose form. 
Formulacije mogu biti u jediničnim ili multi-doznim sistemima.
The method of claim 11, wherein the HBV gene expression or replication of HBV is inhibited by at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98% or about 100%. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da se ekspresija ili replikacija gena HBV inhibira najmanje oko 30%, oko 40%, oko 50%, oko 60%, oko 70%, oko 80%, oko 90%, oko 95%, oko 98% ili oko 100%.
a step of producing the compound of the formula (7) from the compound of the formula (7a): (in the formula, Lv represents leaving group, Me represents methyl, iPr represents isopropyl, and R represents isopropyl or (2R)-2-fluoropropyl); 
[image] (u formuli Lv predstavlja izlaznu skupinu, Me predstavlja metil, iPr predstavlja izopropil, a R predstavlja izopropil ili (2R)-2-fluorpropil);
A preferred embodiment is directed to such a method of recycling a solid support for cultivation of anchorage-dependent cells wherein said aqueous solution is water. 
Poželjna izvedba se odnosi na takav postupak za recikliranje krutih potpora za uzgoj stanica koje potrebuju pričvršćivanje, gdje spomenuta vodena otopina je voda.
is a hydrogen atom or fluorine atom or chlorine atom; 
- X, je vodikov atom ili fluorov atom ili klorov atom; skupinu;
The compound according to Claim 1, or a salt or solvate thereof, wherein A5is NR5 and R5 is a hydrogen atom. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova sol ili solvat, naznačen time što je A? NR", a R? je atom vodika.
From the base 14 there extends, towards the sole 2 and rearwardly from the second appendix 20, a third appendix 23, shaped substantially like the cavity 13 and having a longitudinal extension less than such cavity, slidably lodged in such cavity 13 for guiding and limiting the sliding of the buttress element 5 longitudinally to the sole 2; the second appendix 20 constitutes said guiding means of the axial position with respect to the sole 2. 
Od osnovice 14 prema potplatu 2 1 na stražnju stranu od drugog nastavka 20 1de treći nastavak 23, oblikovan uglavnom kao gnijezdo 13, koji ima uzdužnu duljinu manju od dužine gnijezda, klizno se može smjestiti u to gnijezdo 13 za vođenje i ograničenje klizanja potpornog clemcnta 5 uzdužno u odnosu na potplat 2, a drugi nastavak 20 tvori spomenuto vodilo aksijalnog položaja u odnosu na potplat 2.
Further objects, advantages and features of the dual phase steel strip according to the present invention will be clearer from the following description with reference to the annexed drawings in which: 
Slijedeći ciljevi, prednosti i krakteristike dvofazne čelične trake prema ovom izumu biti će jasniji iz slijedećeg opisa u svezi sa priloženim crtežima u kojima:
A compound according to any one of claims 1 or 3 to 7, wherein R6 represents a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C1-C4 alkoxy group, a C1-C4 haloalkyl group, a C1-C4 hydroxyalkyl group, a C3-C4 cycloalkyl group, a -(CH2)0-3NR'R" group, or a linear or branched C1-C4 alkyl group, which alkyl group is unsubstituted or substituted by a C1-C3 alkoxy group; wherein R' and R" each independently represent a hydrogen atom, a hydroxy group, or a linear or branched C1-C3 alkyl group; 
predstavlja atom vodika, atom halogena, hidroksilnu grupu, cijano grupu, C1-C4 alkoksi grupu, C1-C4 haloalkilnu grupu, C1-C4 hidroksialkilnu grupu, C3-C4 cikloalkilnu grupu, -(CH2)0-3NR'R'' grupu ili linearnu ili razgranatu C1-C4 alkilnu grupu, pri čemu je alkilna grupa nesupstituirana ili supstituirana C1-C3alkoksi grupom; naznačen time, što R' i R'' svaki zasebno predstavljaju atom vodika, hidroksilnu grupu ili linearnu ili razgranatu C1-C3 alkilnu grupu;
The composition of Claim 10 in the form of a soil drench liquid formulation. A spray composition for controlling an invertebrate pest, comprising: 
Smjesa iz Zahtjeva 10, naznačena time, što je u formi tekuće formulacije za natapanje zemljišta.
After release of the actuation member 17, the biasing force of spring 15 returns the valve element 5 and actuation member 17 to the intermediate position shown in FIG. 9, and thus, stops discharge of fluid 4 from the metering chamber 6 . 
Nakon rasterećenja elementa za pokretanje 17, sila prenaprezanja opruge 15 vraća element ventila 5 i element za pokretanje 17 u međupoložaj prikazan na slici 9 i, stoga, dakle, zaustavlja pražnjenje tekućine 4 iz odmjerne komore 6.
These beams 35, 36 provide rigidity to the large wall element 2 and provide a means for attaching the wall element 2 to the auxiliary columns 31 and any window to the wall element 2. 
Ove grede 35, 36 osiguravaju krutost velikom zidnom elementu 2 i omogućavaju spajanje zidnog elementa 2 s pomoćnim stupovima 31 i bilo kojeg prozora sa zidnim clementom 2.
The compound as recited in Claim 1, wherein said muscular dystrophy is Duchenne muscular dystrophy. 
VBPI5 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedena mišićna distrofija Duchenne mišićna distrofija.
The rodent of claim 10, wherein the rodent expresses a population of antigen-specific antibodies in response to an antigen of interest wherein all antibodies from the population comprise: 
Glodavac prema zahtjevu 10, naznačen time, što glodavac izražava populaciju antitijela specifičnih za antigen kao odgovor na interesni antigen, pri čemu sva antitijela iz populacije sadrže:
A composition for use according to claim 3, wherein the patient has a rate of urine production during sleep that is greater than the patient's overall average daily rate of urine production. 
Pripravak za uporabu prema zahtjevu 11, naznačen time da pacijent ima stopu proizvodnje urina tijekom spavanja veću od prosječne stope cjelodnevne proizvodnje urina pacijenta.
wherein the first piston part and the second piston part move co-axially, or 
naznačen time da se prvi dio klipa i drugi dio klipa pomiču ko-aksijalno, ili
The composition of claim 1, the compound comprising a structure of Formula 5 or stereoisomer thereof or pharmaceutically acceptable salt thereof. 
RH I s u NE s k s 1, tvar sadrži strukturu Formule 5 ili njen stereoizomer ili njenu farmaceutski
Cells were grown in 1-175 flasks or Costar black, clear-bottomed 96-well view plates and maintained at 37° C. in a 90% humidified incubator with an atmosphere of 5% CO2 and 95% air. 
Stanice su rasle u tikvicama T-175 ili pločicama s 96 jamica Costar black, čistog dna i držane su pri 37"C u 90%-tnom vlažnom inkubatoru s atmosferom od 5% CO, 1 95% zraka.
A compound of claim 8 or the use of claim 10, wherein the disorder is selected from the group consisting of age-associated memory impairment, mild cognitive impairment, pre-senile dementia (early onset Alzheimer's disease), senile dementia (dementia of the Alzheimer's type), Lewy body dementia, vascular dementia, Alzheimer's disease, stroke, AIDS dementia complex, attention deficit disorder, attention deficit hyperactivity disorder, dyslexia, schizophrenia, schizophreniform disorder and schizoaffective disorder. 
Spoj prema zahtjevu 2, kompozicija prema zahtjevima 3 ili 4, ili upotreba prema zahtjevu 5, gdje se poremećaji biraju iz skupine koju čine neusaglašenost memorije uslijed starenja, blaga kognitivna neusaglašenost, pre-senilna demencija (rani početak pojave Alzheimerove bolesti), senilna demencija (demencija Alzheimerovog tipa), demencija sa Lewyjevim tijelima, vaskularna demencija, Alzheimerova bolest, moždani udar, kompleks AIDS demencije, poremećaj smanjenja pažnje, kognitivni deficit, poremećaj hiperaktivnosti uslijed smanjenja pažnje, disleksija, shizofrenija, poremećaji shizofrenog oblika i shizoafektivni poremećaji.
dose b of tapentadol during a second administration interval following the first administration interval,where dose a < dose b. 
- < doza b tapentadola daje tijekom drugog intervala davanja nakon navedenog prvog intervala davanja, pri čemu je doza a < doze b.
The selection epitope of claim 12, wherein the selection epitope is for use in a use selected from: 
Epitop za odabir iz zahtjeva 12, pri čemu se isti upotrebljava kao:
steel, optionally pre-treated to be corrosion resistant and adhesive to the coating composition. 
čelična, koja je prema potrebi prethodno obrađena tako da bude otporna prema koroziji i da je adhezivna prema sastavu premaza.
The method according to claim 26, wherein before the step of adding the Grignard reagent of the formula IX to the thiolactone of the formula VIII to obtain a compound V, about 0.8 to 1.2 equivalents of R30MgX (R30 represents a C1-8 alkyl group or a C3-7 cycloalkyl group, and X represents a halogen atom) is added to the thiolactone of the formula VIII. 
Postupak prema zahtjevu 26, naznačen time da se prije koraka dodavanja Grignardovog reagensa formule IX u tiolakton formule VIII da se dobije spoj V, oko 0.8 do 1.2 ekvivalenata R*MgX (R" predstavlja C.g alkil skupinu ili C3.; cikloalkil skupinu, te X predstavlja atom halogena) dodaje u tiolakton formule VIII.
generating information about a maximum coding unit, used to split an image into a plurality of square maximum coding units; 
Neprenosiv računalno čitljiv medij za pohranu koji pohranjuje tok bitova koji obuhvaća: informaciju o maksimalnoj veličini jedinice kodiranja, koja se koristi za podjelu slike u mnoštvo kvadratnih maksimalnih jedinica za kodiranje;
Another particular embodiment of the invention is the aqueous pharmaceutical suspension, wherein the pH is about 5.00 to about 8.00; or more particularly 5.80 to about 7.00. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 1, naznačena time što pH je otprilike 5,80 do otprilike 7,00.
Such buprenorphine transdermal delivery systems may be a laminated composite having an impermeable backing layer containing buprenorphine, and optionally, a permeation enhancer, and a pressure-sensitive adhesive. 
Takvi transdermalni sustavi izdavanja buprenorfina mogu biti laminiranog sastava te imati nepropusni sloj podstave koji sadrži buprenorfin, te opcionalno, poboljšivač prodiranja, te na pritisak osjetljivo ljepilo.
The method of claim 16, wherein the population of progeny T cells persist in the human for at least four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration. The method of claim 16, wherein the cancer is treated. 
T stanica za upotrebu prema patentnom zahtjevu 10, naznačena time što populacija potomstva T stanica perzistira u čovjeku najmanje tri mjeseca, četiri mjeseca, pet mjeseci, šest mjeseci, sedam mjeseci, osam mjeseci, devet mjeseci, deset mjeseci, jedanaest mjeseci, dvanaest mjeseci, dvije godine, ili tri godine nakon primjene.
The process according to claim 4, wherein said polar aprotic solvent is selected from the group consisting of tetrahydrofuran, dimethyl formamide, and N-methylpyrrolidone. 
Postupak prema patentnom zahljevu 4, naznačen time da je polarno aprotično otapalo izabrano iz skupine koja sadrži tetrahidrofuran, dimetil formamid, i N-metilpirolidon.
from 0 to 6% by weight of an inorganic carbonate, and veterinarily acceptable adjuvants and/or excipients, as an anti-inflammatory and/or antimicrobial agent for use in the prevention and treatment of foot diseases in ungulates. 
€) od 0 do 6 težinskih % neorganskog karbonata, i veterinarski prihvatljive adjuvante i/ili inertne punitelje, kao anti-inflamatorno i/ili antimikrobialno sredstvo za uporabu u prevenciji 1 liječenju bolesti stopala kod papkara i kopitara.
wherein also the coupling parts at the second pair of edges form a first locking system which effects a locking in the plane of the panels and perpendicular to the respective edges, as well as form a second locking system which effects a locking perpendicular to the plane of the panels; 
gdje ovi dijelovi (6-7, 8-9) za spajanje, na oba para rubova (2-3, 4-5), formiraju prvi sistem za zaključavanje koji vrši zaključavanje u ravninom panela i okomito u odnosu na odgovarajuće rubove, kao što i formiraju drugi sistem za zaključavanje koji vrši zaključavanje poprečno u odnosu na ravninu panela;
a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab after storage at 25°C for 3 to 6 months of less than 5 %; 
(b) tekući vodeni farmaceutski pripravci koja sadržava terapeutski učinkovitu količinu Adalimumaba u puferiranoj otopini koja sadržava L-histidin i citrat, a spomenuta formulacija ima pH od 5 do 5,5 i ima sadržaj agregiranih vrsta Adalimumaba, nakon skladištenja pri 25 "€ tijekom 3 do 6 mjeseci, manje od 5 %;
or a salt thereof wherein R1 is hydrogen or an amino protecting group. 
ili njegova sol, gdje R! je vodik ili jedna amino-zaštitna skupina.
Preferably, R is a moiety of formula: 
R je skupina formule -A-Y-Z, gdje,
A nasal spray device as claimed in claim 1, wherein the pharmaceutical formulation is a solution formulation. 
Nazalni raspršivač za nos sukladno zahtjevu 1, pri čemu farmaceutski pripravak predstavlja pripravak otapala.
removing said tube at the end of the administration; wherein the pulmonary surfactant suspension is applied at a concentration of at least 40 mg/ml and has a viscosity lower than 20 mPas. 
farmaceutski pripravak koji sadrži od 40 do 80 mg/ml plućnog surfaktanta suspendiranog u ne više od 3.0 ml farmaceutski prihvatljivog vodenog medija u jedinici doze, a rečeni pripravak ima viskoznost manju od 20 mPas;
represents, independently at each occurrence, hydrogen, halogen, cyano, trifluoromethyl, nitro, —ORa, SRa, SORa, —SO2Ra, —SO2NRaRb, —NRaRb, —NRaCORb, —NRaCO2Rb, —CORa, —CO2Ra, —CONRaRb, or a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom; 
KHOH=O(CHJCO,H. gdje R* i R* nezavisno predstavljaju, pri svakom pojavljivanju, vodik, ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, 1li heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom; i nje 0, 1, 2,3 ili 4; ili farmaceutski prihvatljiv solvat ili, pobliže, njenu sol; za uporabu u liječenju osteoporoze i/ili osteopenije.
Finally, Fig. 
Na kraju, sl.
Nevertheless, with an angular position of −90°, the centrifugal forces are combined in the downward direction (A), and given the attachment with the tooth (1), they pull on it, generating the greater downward force vector on the axis (7) of the tooth (1), impacting on the ground. 
Hidraulički čekić razbijač u skladu s patentnim zahtjevom 1 pri čemu su, u izvučenoj poziciji (B) zuba (1), ekscentri (2,3) smješteni u kutnoj poziciji od -90%, povlačeći zub (1) na dolje.
In case of mild cognitive impairment, these are patients that have remained clinically, neuropsychologically, or cognitively stable for years in spite of their annual statistical risk of more than 20% for developing a neurodegenerative disease that is clinically manifest and progressive in the further course. Thus, in one embodiment said surrogate marker is selected from the group consisting of old age, brain amyloid load, ApoE genotype, APP genotype, PS1 genotype, levels in body fluids of Abeta peptide, isoprostanes, Tau, and phospho-Tau. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da je kod navedenog bolesnika utvrđeno da pati od poremećaja koji se još nije manifestirao ili postoji rizik da bi mogao razviti poremećaj zbog prisutnosti ili odsutnosti surogatnog markera, pri čemu je poželjno da je navedeni surogatni marker odabran iz skupine koja obuhvaća starost, amiloidno opterećenje mozga, ApoE genotip, APP genotip, PSI genotip, razine tjelesnih tekućina Abeta peptida, izoprostan, Tau i fosfo-Tau.
A sensor assembly according to claim 6, wherein said second Bragg grating (1416) is provided as a substance-sensing grating and the sensor assembly further comprises a second longitudinal-strain-inducing jacket coating (1412C) coupled to said first longitudinal-strain-inducing jacket of said first optical fiber and extending along a longitudinal axis, said second longitudinal-strain-inducing jacket coating selected and configured to induce axial strain in said first optical fiber at said second Bragg grating as a function of presence of a substance. 
Senzoričko sklopovlje u skladu s patentnim zahtjevom 6, naznačeno time što je navedena druga Braggova rešetka (1416) postavljena kao rešetka za senzoriku tvari, gdje senzoričko sklopovlje dodatno sadrži drugu oblogu koja uzrokuje uzdužno naprezanje (1412C), spregnutu s navedenom prvom oblogom koja uzrokuje uzdužno naprezanje navedenog prvog optičkog vlakna i pruža se po uzdužnoj osi, gdje je navedena druga obloga koja uzrokuje uzdužno naprezanje odabrana i konfigurirana da uzrokuje aksijalno naprezanje u navedenom prvom optičkom vlaknu kod navedene druge Braggove rešetke kao funkciju prisutnosti tvari.
verifying, by the second aerial vehicle, which one among the third and the fourth code matches with the second code stored in the second memory; and 
- - Verifikaciju, pomoću drugog zračnog prometala, trećeg 1 četvrtog koda kako bi se utvrdilo koji odgovara drugom kodu pohranjenom u drugoj memoriji; i
The composition for the use of claim 1 or 2, wherein the extranodal lymphoma includes central nervous system (CNS), cutaneous tissue, breast, lungs, liver, gastrointestinal tract, genitourinary tract, ocular tissue, bone marrow and/or bones. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što ekstranodalni limfom uključuje središnji živčani sustav (CNS), kutano tkivo, dojke, pluća, jetru, gastrointestinalni sustav, genitourinarni sustav, očno tkivo, koštanu srž i/ili kosti.
A compound selected from: or or a pharmaceutically acceptable salt thereof. 
[image] [image] [image] [image] ili njihova farmaceutski prihvatljiva sol.
Furthermore, the present invention relates to the use of said composition for the treatment of anal rhagades. 
Spoj za primjenu prema zahtjevima 1 ili 2 za primjenu u liječenju analnih ragada.
The pharmaceutical composition according to claim 1 wherein the perforated microstructures comprise a spray-dried emulsion of perfluorooctyl bromide, DSPC and calcium chloride in water. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što perforirane mikrostrukture sadrže emulziju perfluoroktil-bromida, DSPC (1,2-disteroil-sn-glicero-3-fosfokolin) i kalcijevog klorida osušenih raspršivanjem u vodi.
The invention also relates to the antibody of the invention for use in a method of treatment of a tumorigenic disease or for sensitizing of tumor cells in a patient for the treatment with a chemotherapeutic drug or with radiotherapy. 
Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 10, točka (ii), naznačena time što se kemoterapijski lijek ili radioterapija primjenjuje prije vežuće molekule.
4 is a schematic partial section of the discharge device with the metered dose valve according to the first embodiment of the present invention in the first position; 
prikazuje shematski djelomičan presjek naprave za pražnjenje s ventilom za odmjeravanje doze prema prvoj izvedbi predloženog izuma u prvom položaju;